- Home
- NMRK vs CPRX Comparison
NMRK vs CPRX Comparison
Compare NMRK & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- CPRX
- Stock Information
- Founded
- NMRK 1929
- CPRX 2002
- Country
- NMRK United States
- CPRX United States
- Employees
- NMRK N/A
- CPRX N/A
- Industry
- NMRK Real Estate
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- CPRX Health Care
- Exchange
- NMRK Nasdaq
- CPRX Nasdaq
- Market Cap
- NMRK 2.3B
- CPRX 2.6B
- IPO Year
- NMRK 2017
- CPRX 2006
- Fundamental
- Price
- NMRK $12.11
- CPRX $24.69
- Analyst Decision
- NMRK Buy
- CPRX Strong Buy
- Analyst Count
- NMRK 4
- CPRX 8
- Target Price
- NMRK $16.83
- CPRX $32.50
- AVG Volume (30 Days)
- NMRK 1.1M
- CPRX 1.5M
- Earning Date
- NMRK 05-02-2025
- CPRX 05-07-2025
- Dividend Yield
- NMRK 0.99%
- CPRX N/A
- EPS Growth
- NMRK 41.67
- CPRX 107.94
- EPS
- NMRK 0.34
- CPRX 1.31
- Revenue
- NMRK $2,738,502,000.00
- CPRX $491,734,000.00
- Revenue This Year
- NMRK $13.31
- CPRX $15.17
- Revenue Next Year
- NMRK $8.93
- CPRX $8.28
- P/E Ratio
- NMRK $35.62
- CPRX $18.85
- Revenue Growth
- NMRK 10.85
- CPRX 23.49
- 52 Week Low
- NMRK $9.44
- CPRX $14.47
- 52 Week High
- NMRK $16.10
- CPRX $26.16
- Technical
- Relative Strength Index (RSI)
- NMRK 37.71
- CPRX 62.78
- Support Level
- NMRK $12.26
- CPRX $20.68
- Resistance Level
- NMRK $12.97
- CPRX $26.16
- Average True Range (ATR)
- NMRK 0.41
- CPRX 0.83
- MACD
- NMRK -0.01
- CPRX 0.36
- Stochastic Oscillator
- NMRK 26.50
- CPRX 75.21
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.